Besides the ASCENT study, the LAURA trial (NCT03521154) is currently evaluating the efficacy of osimertinib as a consolidative treatment after chemoradiation in patients with unresectable stage III EGFR mutant NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.